Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells injected directly into the brain show promise for childhood cancers

NCT ID NCT04185038

First seen Jan 10, 2026 · Last updated May 12, 2026 · Updated 16 times

Summary

This early-stage study is testing whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG or recurrent medulloblastoma. The cells are designed to recognize and attack a protein called B7-H3 found on many tumor cells. The main goals are to see if the treatment is safe and possible to make, and to learn how the cells move through the brain and body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Seattle Children's Hospital

    RECRUITING

    Seattle, Washington, 98105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.